Literature DB >> 21550636

Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis.

Toni K Choueiri1, Fabio A B Schutz, Nathanael D Hevelone, Paul L Nguyen, Stuart R Lipsitz, Stephen B Williams, Stuart G Silverman, Jim C Hu.   

Abstract

OBJECTIVE: To evaluate contemporary national practice pattern trends in the use of thermal ablation (radiofrequency ablation and cryoablation) in the management of stage I renal cell carcinoma (RCC), and the factors that lead to using thermal ablation (TA) vs partial (PN) or radical nephrectomy (RN) in the United States.
METHODS: Within the Surveillance, Epidemiology and End Results (SEER) database, we identified subjects with T1-N0M0 RCC treated with either PN, RN, or TA between 2004 and 2007. Proportions, trends, and multivariable logistic regression models tested the predictors of the use of TA.
RESULTS: In total, 15,145 patients underwent a procedure for an RCC that was organ-confined and ≤7 cm. Of these, 578 underwent TA, 4402 underwent PN, and 10,165 underwent RN. On unadjusted analyses, patients who received TA were more likely to be older, single, have smaller tumor size, be diagnosed in more recent years, and have more unspecified histologic subtype and tumor grade. In multivariable adjusted analyses, single status (P=.02), male gender (P=.01), increasing age (P<.01), year of diagnosis (P<.01), and smaller tumor size (P<.01) were strong independent predictors of TA use compared with surgery (PN or RN). Further adjusted analyses showed no statistical difference in cancer-specific or overall survival between TA vs PN or RN.
CONCLUSIONS: TA use for stage I RCC increased over a relatively short period and was performed more commonly in patients of older age and with smaller tumor size. Longer follow-up is needed to assess the comparative effectiveness of TA vs surgery.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21550636     DOI: 10.1016/j.urology.2011.01.068

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  20 in total

Review 1.  Update on thermal ablation of renal cell carcinoma: oncologic control, technique comparison, renal function preservation, and new modalities.

Authors:  Ronald J Zagoria; David D Childs
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

Review 2.  Evaluation and management of small renal masses: looking beyond the tumor margin.

Authors:  Michael Garcia-Roig; Michael A Gorin; Merce Jorda
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

3.  Safety, efficacy and predictors of local recurrence after percutaneous radiofrequency ablation of biopsy-proven renal cell carcinoma.

Authors:  Michael Z Su; Fatima Memon; Howard M Lau; Andrew J Brooks; Manish I Patel; Henry H Woo; Simon V Bariol; Philip Vladica
Journal:  Int Urol Nephrol       Date:  2016-07-18       Impact factor: 2.370

4.  Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer: A Population-Based Analysis.

Authors:  Adam D Talenfeld; Renee L Gennarelli; Elena B Elkin; Coral L Atoria; Jeremy C Durack; William C Huang; Sharon W Kwan
Journal:  Ann Intern Med       Date:  2018-06-26       Impact factor: 25.391

5.  Ultrasound-guided radiofrequency ablation for cT1a renal masses in poor surgical candidates: mid-term, single-center outcomes.

Authors:  Ioannis Zachos; Konstantinos Dimitropoulos; Anastasios Karatzas; Michael Samarinas; Argiro Petsiti; Vassilios Tassoudis; Vassilios Tzortzis
Journal:  Ther Adv Med Oncol       Date:  2016-06-29       Impact factor: 8.168

6.  [Small renal mass].

Authors:  D Prokofiev; N Kreutzer; A Kress; F Wissing; H Pfeifer; J-U Stolzenburg; A Dietel; T Schwalenberg; M Do; M C Truß
Journal:  Urologe A       Date:  2012-10       Impact factor: 0.639

Review 7.  Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy.

Authors:  Serge Ginzburg; Jeffrey J Tomaszewski; Alexander Kutikov
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

8.  Feasibility of Intraoperative Nerve Monitoring in Preventing Thermal Damage to the "Nerve at Risk" During Image-Guided Ablation of Tumors.

Authors:  Richard H Marshall; Edward K Avila; Stephen B Solomon; Joseph P Erinjeri; Majid Maybody
Journal:  Cardiovasc Intervent Radiol       Date:  2015-12-30       Impact factor: 2.740

Review 9.  Percutaneous biopsy for risk stratification of renal masses.

Authors:  Michael L Blute; Anna Drewry; Edwin Jason Abel
Journal:  Ther Adv Urol       Date:  2015-10

10.  Clinical characteristics associated with treatment type for localized renal tumors: implications for practice pattern assessment.

Authors:  Marc C Smaldone; Gauthami Churukanti; Jay Simhan; Simon P Kim; Jose Reyes; Fang Zhu; Alexander Kutikov; Rosalia Viterbo; David Y T Chen; Richard E Greenberg; Robert G Uzzo
Journal:  Urology       Date:  2013-02       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.